Skip to content

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03448367
Enrollment
19
Registered
2018-02-28
Start date
2018-02-27
Completion date
2020-10-13
Last updated
2021-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

This is a prospective, multi-center, non-randomized, single-arm, post-approval study of the FreeStyle Libre Flash Glucose Monitoring System intended to characterize the safety of the Libre Flash Glucose Monitoring System when used in pediatric patients with diabetes.

Detailed description

Up to 400 pediatric subjects aged 4-17 years with type 1 or type 2 diabetes, who require daily blood glucose monitoring to manage their diabetes, will be enrolled to obtain at least 314 subjects who complete the final visit. Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase). Subjects and/or their caregivers will maintain a diary/log book of Adverse Events during each phase. Assessment of Adverse Events will occur via self reporting at each monthly visit and/or phone call.

Interventions

Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).

Sponsors

Abbott Diabetes Care
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
4 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Subject must be 4 - 17 years of age. * Subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment. * Subject is currently using SMBG for managing their diabetes. * Subject and/or caregiver must be able to read and understand English . * In the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. * Subject and/or caregiver must have access to an internet connected computer for uploading data from the blood glucose meter and FreeStyle Libre system. * Subject must have an overnight companion (caregiver 18 years or older) present in the same home during participation of the study. * Subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate.

Exclusion criteria

* Subject and/or caregiver is a member of the Site Staff. * Subject is currently using or has previously used a continuous glucose monitoring system for managing their diabetes * Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin. * Subject is known to be pregnant or is attempting to become pregnant at the time of enrollment. * Subject is on dialysis at the time of enrollment. * Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. * Subject currently is participating in another clinical trial. * Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Design outcomes

Primary

MeasureTime frameDescription
Safety of the FreeStyle Libre Flash Glucose Monitoring SystemApproximately one year per subject.The study is designed to characterize the safety of the FreeStyle Libre Flash Glucose Monitoring System when used in the pediatric patient population.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026